Alkermes plc (ALKS - Free Report) announced positive top-line data from a phase Ib study evaluating its novel, investigational, oral orexin 2 receptor (OX2R) agonist, ALKS 2680, as a once-daily treatment for narcolepsy.
The above data was from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of the early-stage proof-of-concept study, which evaluated ALKS 2680 for the given indication.
The phase Ib NT2 and IH study cohorts investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of various doses of ALKS 2680 (5 mg, 12 mg and 25 mg).
Data from the study showed that treatment with ALKS 2680 led to clinically meaningful and statistically significant improvements in mean sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo from baseline at all doses tested.
Additionally, treatment with ALKS 2680 was generally well tolerated in both patient populations.
Building upon the success of the above mentioned phase Ib proof-of-concept study, Alkermes is looking to select doses for a phase II study on ALKS 2680 in NT2. The company plans to initiate a phase II study evaluating ALKS 2680 in patients with NT2 during the second half of 2024.
In January 2024, Alkermes completed the narcolepsy type 1 cohort in the phase Ib study evaluating ALKS 2680 for the treatment of narcolepsy.
Per the company, if successfully developed and upon potential approval, ALKS 2680 might have the potential to transform the current treatment landscape for narcolepsy.
However, upon potential approval, ALKS 2680 is likely to face some competition from Axsome’s (AXSM - Free Report) Sunosi (solriamfetol), which is presently marketed in the United States for the treatment of narcolepsy.
Axsome acquired the U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) in May 2022. AXSM began selling Sunosi in the U.S. market in May 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
In February 2023, Axsome entered into a licensing agreement with Pharmanovia to market Sunosi in Europe and some other countries.
Jazz’s other sleep disorder drugs, Xyrem and Xywav, also hold a strong market share.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Alkermes plc (ALKS - Free Report) announced positive top-line data from a phase Ib study evaluating its novel, investigational, oral orexin 2 receptor (OX2R) agonist, ALKS 2680, as a once-daily treatment for narcolepsy.
The above data was from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of the early-stage proof-of-concept study, which evaluated ALKS 2680 for the given indication.
The phase Ib NT2 and IH study cohorts investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of various doses of ALKS 2680 (5 mg, 12 mg and 25 mg).
Data from the study showed that treatment with ALKS 2680 led to clinically meaningful and statistically significant improvements in mean sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo from baseline at all doses tested.
Additionally, treatment with ALKS 2680 was generally well tolerated in both patient populations.
Building upon the success of the above mentioned phase Ib proof-of-concept study, Alkermes is looking to select doses for a phase II study on ALKS 2680 in NT2. The company plans to initiate a phase II study evaluating ALKS 2680 in patients with NT2 during the second half of 2024.
In January 2024, Alkermes completed the narcolepsy type 1 cohort in the phase Ib study evaluating ALKS 2680 for the treatment of narcolepsy.
Per the company, if successfully developed and upon potential approval, ALKS 2680 might have the potential to transform the current treatment landscape for narcolepsy.
However, upon potential approval, ALKS 2680 is likely to face some competition from Axsome’s (AXSM - Free Report) Sunosi (solriamfetol), which is presently marketed in the United States for the treatment of narcolepsy.
Axsome acquired the U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) in May 2022. AXSM began selling Sunosi in the U.S. market in May 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
In February 2023, Axsome entered into a licensing agreement with Pharmanovia to market Sunosi in Europe and some other countries.
Jazz’s other sleep disorder drugs, Xyrem and Xywav, also hold a strong market share.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Get the latest research report on ALKS - FREE
Get the latest research report on JAZZ - FREE
Get the latest research report on AXSM - FREE